ContractSunesis Pharmaceuticals Inc • January 13th, 2021 • Pharmaceutical preparations • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • January 13th, 2021 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of July 30, 2020 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and VIRACTA THERAPEUTICS, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:
VIRACTA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • January 13th, 2021 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • California
This Executive Employment Agreement (this “Agreement”) is entered into as of February 26, 2020, and becomes effective upon Dr. Lisa Rojkjaer’s first date of employment, provided such date occurs on or before May 1, 2020, (the “Effective Date”) by and between Viracta Therapeutics, Inc. (the “Company”), and Dr. Lisa Rojkjaer (“Executive”).
LEASELease • January 13th, 2021 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations
CONSULTING AGREEMENT Effective Date: January 1, 2021 Expiration Date: Earlier of [May 29], 2021 and the Closing of the Merger between Sunesis Pharmaceuticals, Inc. and Viracta Therapeutics, Inc.Consulting Agreement • January 13th, 2021 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • California
This Consulting Agreement (the “Consulting Agreement”) is entered into by and between Sunesis Pharmaceuticals, Inc. (“SUNESIS”) and Dayton Misfeldt (“CONSULTANT”) in connection with and as Exhibit A to the Agreement (the “Agreement”) between the parties of even date herewith. SUNESIS desires to have CONSULTANT serve as a non-exclusive consultant to SUNESIS under the terms of this Agreement. This Consulting Agreement is effective immediately upon the expiration of CONSULTANT’s service with SUNESIS as an employee, such that there is no break in service between his termination of employment and the effectiveness of this Consulting Agreement.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A...Exclusive Collaboration and License Agreement • January 13th, 2021 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • Hong Kong
This EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of November 30, 2018 (the “Effective Date”) by and between SHENZHEN SALUBRIS PHARMACEUTICAL CO. LTD., a company organized under the laws of the People’s Republic of China with a place of business at 37F, Tower B, NEO Building, 6009 Shennan Road, Futian District, Shenzhen, China (“Salubris”), and VIRACTA THERAPEUTICS, INC., a Delaware corporation with a place of business at 2533 South Coast Hwy 101, Suite 210, Cardiff, CA 92007, USA (“Viracta”). Viracta and Salubris may be referred to herein individually as a “Party” and collectively as the “Parties”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A...License Agreement • January 13th, 2021 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS LICENSE AGREEMENT (this “Agreement”) dated as of May 1, 2017 (the “Effective Date”), is entered into between VIRACTA THERAPEUTICS, INC., a Delaware corporation (“Viracta”), and NANTKWEST, INC., a Delaware corporation (“NantKwest”).
VIRACTA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • January 13th, 2021 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • California
This Executive Employment Agreement (this “Agreement”) is entered into as of May 31, 2017 (the “Agreement Date”) by and between Viracta Therapeutics, Inc. (the “Company”), and Ivor Royston (“Executive”), and effective as of April 3, 2017 (the “Effective Date”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A...License Agreement • January 13th, 2021 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
